Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603562 · ClinicalTrials.gov registry record · Phase 1
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
A Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by aTyr Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT02603562 is a Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD) that has completed, run by aTyr Pharma. The registered enrollment target is 8 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT02603562, a Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD), has completed, sponsored by aTyr Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.
Conditions Studied
Interventions
- BIOLOGICAL ATYR1940
Study Locations (7)
Other
- Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET) - Marseille
- Institut de Myologie - Paris
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta - Milan
California
- Stanford University - Stanford
Iowa
- University of Iowa Children's Hospital - Iowa City
Ohio
- OSU Wexner Medical Center - Columbus
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2016-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603562
The ClinicalTrials.gov registry entry for NCT02603562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is aTyr Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Facioscapulohumeral Muscular Dystrophy (FSHD) appearing as the primary indexed condition, and to 1 intervention - of which ATYR1940 is the first listed.
NCT02603562 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT02603562 about?
NCT02603562 is a clinical study titled "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy". The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.
What is the current status of trial NCT02603562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-03-30. Estimated completion is 2016-12-12.
What conditions does trial NCT02603562 study?
This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy (FSHD).
What interventions are being tested in trial NCT02603562?
The interventions under investigation include: ATYR1940 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02603562?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603562 being conducted?
This trial has 7 study locations across California, Iowa, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facioscapulohumeral Muscular Dystrophy (FSHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.